576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients

BACKGROUND: Observational studies suggest that half-dose valganciclovir (VGV) prophylaxis (450 mg daily for normal renal function) is as effective as full-dose (900 mg daily) in preventing CMV infection among kidney transplant recipients (KTR). However, this practice is not supported by current guid...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Open Forum Infect Dis
Autori principali: shi, yiyun, Rogers, Ralph, Vieira, Kendra, Merhi, Basma, Osband, Adena, Bayliss, George, Gohh, Reginald, Morrissey, Paul, Farmakiotis, Dimitrios
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Poster Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777334/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.770
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi